Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.77 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP4 | P49662 | 1/20 | 0.53 |
| ▸ | CASP5 | P51878 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7777439 | 0.93 | HRH4 (0.78) | HRH4HRH3CASP1CASP4CASP5 | |
| Trifluoroacetic Acid SCHEMBL7774442 | 0.85 | HRH4 (0.57) | HRH4HRH3CASP1CASP4CASP5 | |
| SCHEMBL10678810 | 0.82 | HRH4 (0.70) | HRH4HRH3CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL30296862 | 0.82 | HRH4 (0.70) | HRH4HRH3CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL8565532 | 0.82 | HRH4 (0.72) | HRH4HRH3CASP1CASP4CASP5 | |
| SCHEMBL9164939 | 0.82 | HRH4 (0.57) | HRH4HRH3CASP1CASP4CASP5 | |
| SCHEMBL1617816 | 0.82 | HRH4 (0.72) | HRH4HRH3CASP1CASP4CASP5 | |
| SCHEMBL2168885 | 0.82 | HRH4 (0.75) | HRH4HRH3 | |
| SCHEMBL2797830 | 0.81 | HRH4 (0.68) | HRH4HRH3CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL10674357 | 0.81 | HRH4 (0.68) | HRH4HRH3CRHBPCRHR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2923734-B1 | PURINE ANALOGUES AND THEIR USE AS IMMUNOSUPPRESSIVE AGENTS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| US-9730944-B2 | Antiviral activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | disclosed |
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-02-04 | — | — | US | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| US-9193741-B2 | Antiviral activity of bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-11-24 | — | — | US | disclosed |
| EP-2923734-A1 | Purine analogues and their use as immunosuppressive agents | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2015-09-30 | — | — | EP | disclosed |
| EP-2923734-A1 | Purine analogues and their use as immunosuppressive agents | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-RE44205-E1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-RE44205-E1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-02-23 | — | — | US | disclosed |
| WO-2010103130-A2 | NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-09-16 | — | — | WO | disclosed |
| US-5550240-A | Piperazinyl-bis(alkylamino)pyrimidine derivatives and process for preparing same | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1996-08-27 | — | — | US | disclosed |
| EP-0644882-A1 | NOVEL PIPERZINYL-BIS(ALKYLAMINO)PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING SAME | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1995-03-29 | — | — | EP | disclosed |
| WO-1993025539-A1 | NOVEL PIPERZINYL-BIS(ALKYLAMINO)PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1993-12-23 | — | — | WO | disclosed |
| US-4916133-A | Stimulating hair growth | L'OREAL (FR) | 1990-04-10 | — | — | US | disclosed |
| US-4885296-A | FOR INDUCING AND STIMULATING HAIR GROWTH | L'OREAL (FR) | 1989-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | TPMT, STAT6, IL4 | HRH4 113/4885HRH3 418/4885CASP1 893/4885 |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | RNASE1, HAVCR2, RNASEH1 | HRH4 82/4885HRH3 70/4885CASP1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.